# Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma

> **NCT04795869** · PHASE2 · WITHDRAWN · sponsor: **Northwestern University**

## Conditions studied

- Recurrent Angioimmunoblastic T-Cell Lymphoma
- Recurrent Enteropathy-Associated T-Cell Lymphoma
- Recurrent Follicular T-Cell Lymphoma
- Recurrent Hepatosplenic T-Cell Lymphoma
- Recurrent Nodal Peripheral T-Cell Lymphoma With TFH Phenotype
- Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified
- Recurrent Subcutaneous Panniculitis-Like T-Cell Lymphoma
- Refractory Angioimmunoblastic T-Cell Lymphoma
- Refractory Enteropathy-Associated T-Cell Lymphoma
- Refractory Follicular T-Cell Lymphoma
- Refractory Hepatosplenic T-Cell Lymphoma
- Refractory Nodal Peripheral T-Cell Lymphoma With TFH Phenotype
- Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified
- Refractory Subcutaneous Panniculitis-Like T-Cell Lymphoma

## Interventions

- **DRUG:** Brentuximab Vedotin
- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT04795869
- **Lead sponsor:** Northwestern University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-03-01
- **Primary completion:** 2026-03-15
- **Final completion:** 2029-03
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study inactivated due to zero accruals
- **Last updated:** 2023-10-10

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04795869

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04795869, "Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT04795869. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*